Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Results and Discussion
2.1. Characterization of SLNs
2.2. Hemolysis Test
2.3. Cell Proliferation Inhibition Assay
2.4. Cell Migration Assays
2.5. Apoptosis Assay
2.6. Cell Cycle Evaluation
2.7. Cellular Uptake and Competition Suppression Assay
2.8. In Vivo Efficacy Evaluation
3. Materials
3.1. Reagents
3.2. Cell Lines
3.3. Animals
4. Methods
4.1. Preparation of Four CTD-Loaded SLNs
4.2. Characterization
4.3. Hemolysis Test
4.4. Cell Proliferation Inhibition Assay
4.5. Cell Migration Assays
4.6. Apoptosis Assay
4.7. Cell-Cycle Detection
4.8. Cellular Uptake and Competition Suppression Assay
4.9. In Vivo Efficacy Evaluation
4.10. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Sample Availability
References
- Craig, A.J.; von Felden, J.; Garcia-Lezana, T.; Sarcognato, S.; Villanueva, A. Tumour evolution in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 139–152. [Google Scholar] [CrossRef] [PubMed]
- Sagnelli, E.; Macera, M.; Russo, A.; Coppola, N.; Sagnelli, C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection 2020, 48, 7–17. [Google Scholar] [CrossRef] [PubMed]
- Oura, K.; Morishita, A.; Tani, J.; Masaki, T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int. J. Mol. Sci. 2021, 22, 5801. [Google Scholar] [CrossRef] [PubMed]
- Rim, C.H.; Lee, H.Y.; Kim, J.S.; Kim, H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: Should they clash or reconcile? Int. J. Radiat. Biol. 2021, 97, 111–119. [Google Scholar] [CrossRef]
- Talaat, R.M.; Abo-Zeid, T.M.; Abo-Elfadl, M.T.; El-Maadawy, E.A.; Hassanin, M.M. Combined Hyperthermia and Radiation Therapy for Treatment of Hepatocellular Carcinoma. Asian Pac. J. Cancer Prev. 2019, 20, 2303–2310. [Google Scholar] [CrossRef]
- Anwanwan, D.; Singh, S.K.; Singh, S.; Saikam, V.; Singh, R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer 2020, 1873, 188314. [Google Scholar] [CrossRef]
- Kim, W.; Cho, S.K.; Shin, S.W.; Hyun, D.; Lee, M.W.; Rhim, H. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: Comparison with TACE or RFA monotherapy. Abdom. Radiol. 2019, 44, 2283–2292. [Google Scholar] [CrossRef]
- Tan, W.; Deng, Q.; Lin, S.; Wang, Y.; Xu, G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: A systematic review and meta-analysis. Int. J. Hyperth. 2019, 36, 264–272. [Google Scholar] [CrossRef] [Green Version]
- Ueno, A.; Masugi, Y.; Yamazaki, K.; Kurebayashi, Y.; Tsujikawa, H.; Effendi, K.; Ojima, H.; Sakamoto, M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol. Int. 2020, 70, 140–154. [Google Scholar] [CrossRef]
- Iacobazzi, R.M.; Vischio, F.; Arduino, I.; Canepa, F.; Laquintana, V.; Notarnicola, M.; Scavo, M.P.; Bianco, G.; Fanizza, E.; Lopedota, A.A. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. J. Colloid Interface Sci. 2021, 608 Pt 1, 239–254. [Google Scholar] [CrossRef]
- Alqahtani, A.; Khan, Z.; Alloghbi, A.; Said Ahmed, T.S.; Ashraf, M.; Hammouda, D.M. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina 2019, 55, 526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ren, Y.; Kinghorn, A.D. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives. Bioorg. Med. Chem. 2021, 32, 116012. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.H.; Bao, Y.L.; Wu, Y.; Yu, C.L.; Meng, X.; Li, Y.X. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett. 2008, 272, 102–109. [Google Scholar] [CrossRef] [PubMed]
- Song, M.; Wang, X.; Luo, Y.; Liu, Z.; Tan, W.; Ye, P.; Fu, Z.; Lu, F.; Xiang, W.; Tang, L.; et al. Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1. Chem. Biol. Interact. 2020, 317, 108939. [Google Scholar] [CrossRef]
- Yao, H.; Zhao, J.; Wang, Z.; Lv, J.; Du, G.; Jin, Y.; Zhang, Y.; Song, S.; Han, G. Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine. Colloids Surf. B Biointerfaces 2020, 196, 111285. [Google Scholar] [CrossRef]
- Zhou, L.; Zou, M.; Zhu, K.; Ning, S.; Xia, X. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma. Molecules 2019, 24, 3080. [Google Scholar] [CrossRef] [Green Version]
- Pan, Y.; Zheng, Q.; Ni, W.; Wei, Z.; Yu, S.; Jia, Q.; Wang, M.; Wang, A.; Chen, W.; Lu, Y. Breaking Glucose Transporter 1/Pyruvate Kinase M2 Glycolytic Loop Is Required for Cantharidin Inhibition of Metastasis in Highly Metastatic Breast Cancer. Front Pharmacol. 2019, 10, 590. [Google Scholar] [CrossRef] [Green Version]
- Zheng, K.; Chen, R.; Sun, Y.; Tan, Z.; Liu, Y.; Cheng, X.; Leng, J.; Guo, Z.; Xu, P. Cantharidin-loaded functional mesoporous titanium peroxide nanoparticles for non-small cell lung cancer targeted chemotherapy combined with high effective photodynamic therapy. Thorac. Cancer 2020, 11, 1476–1486. [Google Scholar] [CrossRef]
- Su, C.C.; Lee, K.I.; Chen, M.K.; Kuo, C.Y.; Tang, C.H.; Liu, S.H. Cantharidin Induced Oral Squamous Cell Carcinoma Cell Apoptosis via the JNK-Regulated Mitochondria and Endoplasmic Reticulum Stress-Related Signaling Pathways. PLoS ONE 2016, 11, e0168095. [Google Scholar] [CrossRef] [Green Version]
- Hu, S.; Chang, J.; Ruan, H.; Zhi, W.; Wang, X.; Zhao, F.; Ma, X.; Sun, X.; Liang, Q.; Xu, H. Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β-catenin nuclear translocation and LEF1 translation. Int. J. Biol. Sci. 2021, 17, 2504–2522. [Google Scholar] [CrossRef]
- Chen, X.; Zhou, M.; Fan, W.; Yang, M.; Yang, L. Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer. Drug Des. Devel. Ther. 2021, 15, 171–183. [Google Scholar] [CrossRef]
- Naz, F.; Wu, Y.; Zhang, N.; Yang, Z.; Yu, C. Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways. Molecules 2020, 25, 3279. [Google Scholar] [CrossRef] [PubMed]
- Sun, S.; Shang, E.; Ju, A.; Li, Y.; Wu, Q.; Li, Q.; Yang, Y.; Guo, Y.; Yang, D.; Lv, S. Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: An in vivo and in vitro study. Fitoterapia 2021, 155, 105033. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Zhang, Y.; Zhang, J.; Guan, C.; Liu, L.; Ren, L. Cantharidin-induced acute hepatotoxicity: The role of TNF-α, IKK-α, Bcl-2, Bax and caspase3. J. Appl. Toxicol. 2020, 40, 1526–1533. [Google Scholar] [CrossRef] [PubMed]
- Zhu, S.S.; Long, R.; Song, T.; Zhang, L.; Dai, Y.L.; Liu, S.W.; Zhang, P. UPLC-Q-TOF/MS Based Metabolomics Approach to Study the Hepatotoxicity of Cantharidin on Mice. Chem. Res. Toxicol. 2019, 32, 2204–2213. [Google Scholar] [CrossRef]
- Wang, G.; Dong, J.; Deng, L. Overview of Cantharidin and its Analogues. Curr. Med. Chem. 2018, 25, 2034–2044. [Google Scholar] [CrossRef]
- Paliwal, R.; Paliwal, S.R.; Kenwat, R.; Kurmi, B.D.; Sahu, M.K. Solid lipid nanoparticles: A review on recent perspectives and patents. Expert Opin. Ther. Pat. 2020, 30, 179–194. [Google Scholar] [CrossRef]
- Dhiman, N.; Awasthi, R.; Sharma, B.; Kharkwal, H.; Kulkarni, G.T. Lipid Nanoparticles as Carriers for Bioactive Delivery. Front. Chem. 2021, 9, 580118. [Google Scholar] [CrossRef]
- Bayón-Cordero, L.; Alkorta, I.; Arana, L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials 2019, 9, 474. [Google Scholar] [CrossRef] [Green Version]
- Lazăr, L.F.; Olteanu, E.D.; Iuga, R.; Burz, C.; Achim, M.; Clichici, S.; Tefas, L.R.; Nenu, I.; Tudor, D.; Baldea, I. Solid Lipid Nanoparticles: Vital Characteristics and Prospective Applications in Cancer Treatment. Crit. Rev. Ther. Drug Carrier Syst. 2019, 36, 537–581. [Google Scholar] [CrossRef]
- Senthil Kumar, C.; Thangam, R.; Mary, S.A.; Kannan, P.R.; Arun, G.; Madhan, B. Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells. Carbohydr. Polym. 2020, 231, 115682. [Google Scholar] [CrossRef] [PubMed]
- Tian, G.; Pan, R.; Zhang, B.; Qu, M.; Lian, B.; Jiang, H.; Gao, Z.; Wu, J. Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA. Front. Pharmacol. 2019, 10, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, K.; Zhou, L.; Zou, M.; Ning, S.; Liu, S.; Zhou, Y.; Du, K.; Zhang, X.; Xia, X. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency. J. Pharm. Sci. 2020, 109, 2038–2047. [Google Scholar] [CrossRef] [PubMed]
- Kharkar, P.S.; Soni, G.; Rathod, V.; Shetty, S.; Gupta, M.K.; Yadav, K.S. An outlook on procedures of conjugating folate to (co)polymers and drugs for effective cancer targeting. Drug Dev. Res. 2020, 81, 823–836. [Google Scholar] [CrossRef] [PubMed]
- Dharmatti, R.; Miyatake, H.; Nandakumar, A.; Ueda, M.; Kobayashi, K.; Kiga, D.; Yamamura, M.; Ito, Y. Enhancement of Binding Affinity of Folate to Its Receptor by Peptide Conjugation. Int. J. Mol. Sci. 2019, 20, 2152. [Google Scholar] [CrossRef] [Green Version]
- Anwar, D.M.; Khattab, S.N.; Helmy, M.W.; Kamal, M.K.; Bekhit, A.A.; Elkhodairy, K.A.; Elzoghby, A.O. Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma. Bioconjug. Chem. 2018, 29, 3026–3041. [Google Scholar] [CrossRef]
- Zhu, D.; Wu, S.; Hu, C.; Chen, Z.; Wang, H.; Fan, F.; Qin, Y.; Wang, C.; Sun, H.; Leng, X. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Acta Biomater. 2017, 58, 399–412. [Google Scholar] [CrossRef] [PubMed]
- Hanafy, N.A.N.; Quarta, A.; Di Corato, R.; Dini, L.; Nobile, C.; Tasco, V.; Carallo, S.; Cascione, M.; Malfettone, A.; Soukupova, J. Hybrid polymeric-protein nano-carriers (HPPNC) for targeted delivery of TGFβ inhibitors to hepatocellular carcinoma cells. J. Mater. Sci. Mater. Med. 2017, 28, 120. [Google Scholar] [CrossRef]
- Liu, M.; Tu, J.; Feng, Y.; Zhang, J.; Wu, J. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma. J. Nanobiotechnol. 2020, 18, 114. [Google Scholar] [CrossRef]
- Pizzol, C.D.; Filippin-Monteiro, F.B.; Restrepo, J.A.; Pittella, F.; Silva, A.H.; Alves de Souza, P.; Machado de Campos, A.; Creczynski-Pasa, T.B. Influence of surfactant and lipid type on the physicochemical properties and biocompatibility of solid lipid nanoparticles. Int. J. Environ. Res. Public Health 2014, 11, 8581–8596. [Google Scholar] [CrossRef]
- Jansook, P.; Pichayakorn, W.; Ritthidej, G.C. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): Effect of drug loading and biopharmaceutical characterizations. Drug Dev. Ind. Pharm. 2018, 44, 1693–1700. [Google Scholar] [CrossRef]
- Tang, Z.H.; Li, T.; Chang, L.L.; Zhu, H.; Tong, Y.G.; Chen, X.P.; Wang, Y.T.; Lu, J.J. Glycyrrhetinic acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. J. Agric. Food Chem. 2014, 62, 11910–11916. [Google Scholar] [CrossRef]
- National Pharmacopoeia Committee. Chinese Pharmacopoeia, Part IV (2020 Edition) [S]; Medical Science Press: Beijing, China, 2020.
- Hou, G.; Qian, J.; Guo, M.; Xu, W.; Wang, J.; Wang, Y.; Suo, A. Hydrazided hyaluronan/cisplatin/indocyanine green coordination nanoprodrug for photodynamic chemotherapy in liver cancer. Carbohydr. Polym. 2022, 276, 118810. [Google Scholar] [CrossRef]
Samples | Particle (Sizenm) | PDI | Zeta-Potential (mV) | EE(%) | DL(%) |
---|---|---|---|---|---|
CSLNs | 75.42 ± 1.14 | 0.191 ± 0.013 | −9.66 ± 0.18 | 96.75 ± 0.26 | 0.37 ± 0.02 |
GA-CSLNs | 105.43 ± 2.75 | 0.495 ± 0.011 | −10.80 ± 0.16 | 96.31 ± 0.26 | 0.35 ± 0.03 |
FA-CSLNs | 75.91 ± 0.71 | 0.202 ± 0.007 | −10.98 ± 0.87 | 96.95 ± 0.39 | 0.38 ± 0.02 |
GA-FA-CSLNs | 78.01 ± 1.03 | 0.487 ± 0.015 | −10.16 ± 0.11 | 95.98 ± 0.21 | 0.32 ± 0.04 |
Number | Sample (mL) | 0.9% NaCl Solution (mL) | 2% Red Blood Cell Suspension (mL) | Deionized Water (mL) |
---|---|---|---|---|
1 | 0.2 | 2.3 | 2.5 | 0 |
2 | 0.3 | 2.2 | 2.5 | 0 |
3 | 0.4 | 2.1 | 2.5 | 0 |
4 | 0.5 | 2.0 | 2.5 | 0 |
5 | 0.6 | 1.9 | 2.5 | 0 |
6 | 0.7 | 1.8 | 2.5 | 0 |
7 | 0.0 | 2.5 | 2.5 | 0 |
8 | 0.0 | 0.0 | 2.5 | 2.5 |
9 | 0.7 | 4.3 | 0.0 | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Xu, Y.; Wang, M.; Ning, S.; Yang, Z.; Zhou, L.; Xia, X. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma. Molecules 2022, 27, 6786. https://doi.org/10.3390/molecules27206786
Xu Y, Wang M, Ning S, Yang Z, Zhou L, Xia X. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma. Molecules. 2022; 27(20):6786. https://doi.org/10.3390/molecules27206786
Chicago/Turabian StyleXu, Yilin, Min Wang, Shuangcheng Ning, Zhonglan Yang, Lili Zhou, and Xinhua Xia. 2022. "Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma" Molecules 27, no. 20: 6786. https://doi.org/10.3390/molecules27206786